外科理论与实践 ›› 2019, Vol. 24 ›› Issue (05): 465-469.doi: 10.16139/j.1007-9610.2019.05.018
李帅 综述, 陈小松, 沈坤炜 审校
收稿日期:
2019-08-02
出版日期:
2019-10-05
发布日期:
2019-10-05
通讯作者:
沈坤炜,E-mail: kwshen@medmail.com.cn
Received:
2019-08-02
Online:
2019-10-05
Published:
2019-10-05
中图分类号:
李帅, 陈小松, 沈坤炜. 激素受体阳性乳腺癌延长内分泌治疗的共识和争议[J]. 外科理论与实践, 2019, 24(05): 465-469.
[1] Waks AG, Winer EP.Breast cancer treatment[J]. JAMA,2019,321(3):316. [2] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials[J]. Lancet,2011,378(9793):771-784. [3] Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials[J]. Lancet,2015,386(10001):1341-1352. [4] Pan H, Gray R, Braybrooke J, et al.20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years[J]. N Engl J Med,2017,377(19):1836-1846. [5] Burstein HJ, Temin S, Anderson H, et al.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update[J]. J Clin Oncol,2014,32(21):2255-2269. [6] Davies C, Pan H, Godwin J, et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet,2013,381(9869):805-816. [7] Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J]. J Clin Oncol,31,2013(suppl;abstr5). [8] Tormey DC, Gray R, Falkson HC.Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer[J]. J Natl Cancer Inst,1996,88(24):1828-1833. [9] Stewart HJ, Prescott RJ, Forrest AP.Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years[J]. J Natl Cancer Inst,2001,93(6):456-462. [10] Fisher B, Dignam J, Bryant J, et al.Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial[J]. J Natl Cancer Inst,2001,93(9):684-690. [11] Al-Mubarak M, Tibau A, Templeton AJ, et al.Extended adjuvant tamoxifen for early breast cancer: a meta-analysis[J]. PLoS One,2014,9(2):e88238. [12] Bartlett J, Sgroi D, Treuner K, et al. Breast Cancer Index predicts benefit of extended endocrine therapy in HR+ breast cancers treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial[J]. Ann Oncol,2019.pii:mdz289. [13] Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2009,pii: mdz189. doi: 10.1093/annonc/mdz189. [14] NCCN. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 2.2019) [DB/OL]. [2019-08-02].http://www.nccn.org. [15] Goss PE, Ingle JN, Martino S, et al.Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17[J]. J Natl Cancer Inst,2005,97(17):1262-1271. [16] Goss PE, Ingle JN, Pater JL, et al.Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen[J]. J Clin Oncol,2008,26(12):1948-1955. [17] Mamounas EP, Jeong JH, Wickerham DL, et al.Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial[J]. J Clin Oncol,2008,26(12):1965-1971. [18] Jakesz R, Greil R, Gnant M, et al.Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a[J]. J Natl Cancer Inst,2007,99(24):1845-1853. [19] Gray R. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women[EB/OL]. Presented at2018 SABCS, December 4-8, 2018; San Antonio, Abstract GS3-03.[2019-08-02]. https://www.abstracts2view.com/sabcs/view.php?nu=SABCS18L_1589 [20] Sgroi DC, Carney E, Zarrella E, et al.Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker[J]. J Natl Cancer Inst,2013,105(14):1036-1042. [21] Burstein HJ, Lacchetti C, Anderson H, et al.Adjuvant endocrine therapy for women with hormone receptor-po-sitive breast cancer: ASCO clinical practice guideline focused update[J]. J Clin Oncol,2019,37(5):423-438. [22] Goss PE, Ingle JN, Pritchard KI, et al.Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med,2016,375(3):209-219. [23] Mamounas EP, Bandos H, Lembersky BC, et al.Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol,2019,20(1): 88-99 [24] Ohtani S, Iijima K, Higaki K, et al. A prospective randomized multi-center open-label phase Ⅲ trial of exten-ding aromatase-inhibitor adjuvant therapy to 10 years-results from1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS)[EB/OL]. Presented at 2018 SABCS, December 4-8, 2018; San Antonio, Abstract GS3-04. [2019-08-02].https://www.abstracts2view.com/sabcs/view.php?nu=SABCS 18L_415 [25] Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, et al. Optimal duration of extended adjuvant endocrine the-rapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05)[J]. J Natl Cancer Inst,2018,110(1).doi: 10.1093/jnci/djx134. [26] Gnant M, Steger G, Greil R, et al. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial[EB/OL]. Presented at2017 San Antonio Breast Cancer Symposium, December 5-9, 2017; San Antonio, TX. Abstract GS3-01. [2019-08-02].https://www.abstracts2view.com/sabcs17/view.php?nu=SABCS17L_676. [27] Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial[J]. Lancet Oncol,2017,18(11):1502-1511. [28] Mastro LD, Mansutti M, Bisagni G, et al. Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase Ⅲ study of Gruppo Italiano Mammella(GIM)[J]. J Clin Oncol,37,2019(suppl;abstr504). [29] Goldvaser H, Barnes TA, Seruga B, et al.Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis[J]. J Natl Cancer Inst,2018,110(1):31-39. [30] Dowsett M, Sestak I, Regan MM, et al.Integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy: CTS5[J]. J Clin Oncol,2018,36(19):1941-1948. [31] Richman J, Ring AE, Dowsett M, et al. Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer[J]. J Clin Oncol,37,2019(suppl;abstr514). [32] Sestak I, Buus R, Cuzick J.Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer a secondary analysis of a rando-mized clinical trial[J]. JAMA Oncol,2018,4(4):545-553. [33] Zhang Y, Schroeder BE, Jerevall PL, et al.A novel Breast Cancer Index for prediction of distant recurrence in HR+ early stage breast cancer with 1 to 3 positive nodes[J]. Clin Cancer Res,2017,23(23):7217-7224. [34] Curtis C, Shah SP, Chin SF, et al.The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups[J]. Nature,2012,486(7403):346-352. [35] Rueda OM, Sammut SJ, Seoane JA, et al.Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups[J]. Nature,2019,567(7748):399-404. |
[1] | 张小丽 李赞 宋达疆 王业成 海涛. 带蒂胸外侧动脉穿支皮瓣在保乳术后即刻乳房重建中的临床应用[J]. 组织工程与重建外科杂志, 2022, 18(5): 382-. |
[2] | 宋达疆 李赞 章一新. 带蒂腹直肌皮瓣联合游离腹壁下动脉穿支皮瓣移植重建胸壁巨大缺损的手术策略[J]. 组织工程与重建外科杂志, 2022, 18(5): 386-. |
[3] | 姚成才 陈明 刘长春 黄传蔷 冼家仪 严国标 陈庞洲. 硅凝胶乳房假体联合钛网补片在早期乳腺癌即刻乳房重建中的应用[J]. 组织工程与重建外科杂志, 2022, 18(3): 247-. |
[4] | 廖晓明 蒋奕 唐玮 杨华伟 姬逸男 韦莉颖. 薄层血管化腹股沟淋巴结皮瓣移植联合反向淋巴显影在继发性上肢淋巴水肿手术中的应用[J]. 组织工程与重建外科杂志, 2022, 18(1): 8-. |
[5] | 宋景涌 汤鹏 钟晓捷 刘侠 孙洋 亢玉 王遥佳 陈安玥 陈怡安 吉训通 周艳虹 蒋曼妃 修骋 穆籣. 吻合口通畅性量化分析应用于乳腺癌腋窝淋巴结清扫术同期预防性淋巴管静脉吻合1例[J]. 组织工程与重建外科杂志, 2022, 18(1): 34-. |
[6] | 陈小松, 沈坤炜, 李宏为. 早期可手术乳腺癌的诊治现状与展望[J]. 外科理论与实践, 2022, 27(05): 385-386. |
[7] | 吴佳毅, 陆裕杰, 何金光, 沈坤炜, 徐华. 乳腺癌术后植入物乳房重建技术[J]. 外科理论与实践, 2022, 27(05): 387-391. |
[8] | 陈益定, 吴世杰. 遗传性乳腺癌外科治疗[J]. 外科理论与实践, 2022, 27(05): 392-395. |
[9] | 谢妍妍, 吕青, 杜正贵. 乳腺腔镜和机器人手术的现状及未来之路——华西医院经验分享[J]. 外科理论与实践, 2022, 27(05): 396-402. |
[10] | 周文斌, 唐新宇, 王水. 局部微波消融技术在乳腺癌治疗中的应用[J]. 外科理论与实践, 2022, 27(05): 403-405. |
[11] | 曹璐, 郑思悦, 陈佳艺. 早期乳腺癌区域淋巴结局部处理[J]. 外科理论与实践, 2022, 27(05): 406-410. |
[12] | 黄蔚, 李恒宇, 丁晓毅. 晚期乳腺癌介入诊疗的价值及应用[J]. 外科理论与实践, 2022, 27(05): 411-415. |
[13] | 舒兰, 陈小松. ER+/HER2-乳腺癌多基因阵列检测应用:ASCO指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2022, 27(05): 416-420. |
[14] | 杨崔燕, 王豪雨, 陈小松, 沈坤炜. 抑癌基因TP53突变状态与三阴性乳腺癌病人预后的研究[J]. 外科理论与实践, 2022, 27(05): 421-428. |
[15] | 潘睿忻 综述, 陈小松, 沈坤炜 审校. 循环肿瘤DNA和循环肿瘤细胞检测乳腺癌微小残留病灶的研究[J]. 外科理论与实践, 2022, 27(05): 463-467. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||